Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine

Busulfan combined with cyclophosphamide (BuCy) has long been considered a standard myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation (HCT), including both nonmalignant conditions and myeloid diseases. Substituting fludarabine for cyclophosphamide (BuFlu) to reduce...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Harris, Andrew C., Boelens, Jaap J., Ahn, Kwang Woo, Fei, Mingwei, Abraham, Allistair, Artz, Andrew, Dvorak, Christopher, Frangoul, Haydar, Freytes, Cesar, Gale, Robert Peter, Hong, Sanghee, Lazarus, Hillard M., Loren, Alison, Mineishi, Shin, Nishihori, Taiga, O’Brien, Tracey, Williams, Kirsten, Pasquini, Marcelo C., Levine, John E.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2018
Matèries:
Transplantation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5998928/
https://ncbi.nlm.nih.gov/pubmed/29844205
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018016956
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars